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Shared cell of origin in a patient with Erdheim-
Chester disease and acute myeloid leukemia 
Erdheim Chester Disease (ECD) is a rare histiocytic
neoplasm that is classified as a macrophage-dendritic cell
neoplasm in the 2016 WHO classification of hematopoi-
etic and lymphoid malignancies.1 Histiocytic neoplasms
have been historically categorized into: 1) Langerhans
cell histiocytosis (LCH), and 2) non-Langerhans histiocy-
tosis (non-LCH), including Erdheim–Chester disease
(ECD), juvenile xanthogranuloma (JXG), and Rosai–
Dorfman disease (RDD).  ECD is a malignant disorder
characterized by accumulation of clonally derived foamy
histiocytes, fibrosis and inflammation affecting multiple
organs including bones, lungs, heart, kidneys, and brain,
presenting as fatigue, bone pain, diabetes insipidus, pan-
hypopituitarism, cerebral and cerebellar disease, cardiac
and pulmonary disease, renal failure and retroperitoneal
and mediastinal fibrosis.3 Approximately 50% of patients
with ECD have a BRAFV600E mutation, and those with
wild-type BRAF generally have other activating muta-
tions in the MAPK pathway.2,4
As an early step in differentiation, hematopoietic stem
cells differentiate to lymphoid and myeloid lineages.
Monocytes are derived from myeloid progenitors. Blood
monocytes can differentiate to macrophages and dendrit-
ic cells. Macrophages are large cells residing in tissues and
are mainly involved in clearing pathogens and debris.
Dendritic cells are antigen presenting cells residing in the
skin, mucosa, and lymphoid tissues and their main job is
antigen presentation and activation of T cells. Dendritic
cells residing in the skin are called Langerhans Cells.
Histiocyte is a general term referring to tissue-resident
macrophages and dendritic cells.4-6 The exact cell of origin
of ECD is not known, but three lines of evidence support
that it arises from myeloid progenitors: 1) similar expres-
sion signatures and BRAFV600E mutations have been found
in histiocytic neoplasms and the blood monocyte and
hematopoietic stem cell/progenitors,7-11 2) histiocytosis
like lesions were generated by xenotransplantation of
CD34+ cells from a patient with ECD11 and 3) approxi-
mately 10% of patients with non-Langerhans
Histiocytosis have concurrent myeloid neoplasms.12 Here
we report a patient with BRAFV600E mutated ECD who
developed BRAFV600E mutated acute monocytic leukemia
(AML-M5). Whole exome sequencing confirmed that the
ECD and AML had multiple shared mutations and arose
from the same cell of origin. This case adds to the current
body of evidence suggesting that ECD should be catego-
rized as a myeloid/myeloproliferative neoplasm with a
chance of progression to acute myeloid leukemia.
An 80 year old man presented with dyspnea on exer-
tion. A computed tomography (CT) scan showed ground
glass opacities with septal wall thickening in the lungs
and retroperitoneal fibrosis (Figure 1A and 1B). Whole
body positron emission tomography (PET) showed
Fludeoxyglucose (FDG) avid sclerotic changes in the tibial
midshafts bilaterally, retroperitoneal, perirenal, and
mediastinal fibrotic changes with mild FDG uptake, and
septal line thickening with increased FDG uptake in the
lungs. Brain magnetic resonance imaging (MRI) showed
scattered white matter T2 hyperintensities. Cardiac MRI
revealed circumferential wall thickening of the right atri-
um with normal left and right ventricular systolic func-
tion. He underwent video-assisted thoracoscopic surgery
and wedge resection of the right lower lobe that con-
firmed ECD. Sections of the lung biopsy showed dense
bands of mixed inflammatory infiltrate, consisting of
small lymphocytes, eosinophils, and clusters of atypical
histiocytic cells. Atypical histiocytic cells stained strongly
positive for CD68 and Factor XIII, weakly positive for
S100, and negative for CD1a. Mutation analysis of lung
tissue was performed using both immunohistochemistry
and polymerase chain reaction (PCR). BRAFV600E
immunostaining was positive in atypical histiocytic cells
(Figure 1C) and PCR testing for the BRAFV600E mutation in
lung tissue confirmed the presence of the mutation. A
CBC was notable for: white blood cell count (WBC)
19,000/mL, absolute neutrophil count (ANC) 15,500/mL,
absolute monocyte count 1760/mL, absolute lymphocyte
count 1750/mL, hemoglobin 10.3 g/dl, and platelet count
213,000mL. The patient was offered enrollment in a
phase 1 clinical trial using Vemurafenib - a selective
BRAFV600E inhibitor - or Interferon a as standard of care.
He chose not to get treatment, and was observed. During
an observation period of over 2 years, he had stable mild
shortness of breath as the main symptom of his ECD. His
labs during this period showed normal electrolytes, nor-
mal renal and liver function tests, WBCs of 16000-
29000/mL, ANC of 14000-27000/mL, absolute monocyte
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Table 1. Mutations identified via exome sequencing. Mutations in up- or down-stream regions are annotated with the nearest gene. 
                                                           Gene Name              Amino Acid Change       Protein Effect                   ECD VAF                          AML VAF
Shared Founding Clone                                  BRAF                                   V600E                         missense                                6.12                                       27.06
                                                                            DNAH6                                intronic                               -                                        4.19                                        19.4
                                                                                 SI                                        C635                              silent                                    2.67                                        19.7
                                                                  ENSG00000252849                         none                                  -                                        1.48                                        27.5
                                                                          NDUFB4                                 none                                  -                                        0.84                                          25
AML-specific                                                     USP9X                                  K506fs                    frameshift del                              0                                          23.08
                                                                           LRRC31                                intronic                               -                                          0                                          25.53
                                                                            MED12                                  G44D                          missense                                   0                                          30.12
                                                                             BICC1                                   R839C                         missense                                0.22                                       17.53
                                                                           FAM47A                                 D275Y                         missense                                   0                                          14.29
                                                                               SPI1                                    A211fs                     frameshift del                              0                                          10.77
ECD-specific                                                   PTPRN2                               intronic                               -                                        6.11                                           0
VAF:  Variant Allele Frequency
counts of 1200-3400/mL, hemoglobin of 11-12 g/dl, and
normal platelet counts. He declined to undergo bone
marrow aspiration and biopsy for further evaluation of
his monocytosis. Analysis of peripheral blood by mor-
phology and flow cytometry showed neutrophilic leuko-
cytosis with no dysplasia or blasts. 
Twenty six months after diagnosis of ECD, he present-
ed with worsening fatigue and shortness of breath. CBC
showed WBC of 57,400/mL, hemoglobin of 10.6 g/dL,
and platelet count of 37,000/mL with 11% circulating
blasts.  Bone marrow aspiration and biopsy revealed
AML-M5, with 80% cellularity and 30% blasts.  Blasts
were positive for myeloperoxidase, CD43, CD68,
lysozyme, CD163 (very small subset), and negative for
CD34, CD117, CD3, CD20, CD79a, CD61, Factor XIIIa,
CD15, CD138, CD1a, S100, cytokeratin, and CD30.
BRAFV600E immunostaining of the bone marrow core
showed diffuse positivity of the blasts for BRAFV600Emuta-
tion (Figure 1D) and PCR testing for BRAFV600E mutation
in bone marrow confirmed the mutation. The patient
was offered treatment with hypomethylating agents or
Vemurafenib but declined and proceeded with palliative
care. He died of progressive leukemia a few weeks later.    
The patient was consented and enrolled in an institu-
tional tissue banking protocol for myeloid malignancies.
DNA was extracted from the ECD specimen (lung tissue
biopsy), the bone marrow specimen (at the time of pro-
gression to AML-M5), and normal skin as a proxy for
germline DNA. Enhanced exome sequencing was per-
formed, utilizing a standard exome reagent with addi-
tional probes for recurrent mutations in AML spiked in
for greater coverage. Further details on sequencing,
somatic variant calling, and clonal inference are described
in the Online Supplementary Methods.
We sequenced the normal skin and AML specimens to
mean coverages of 88x and 142x, respectively. The very
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Figure 1. Imaging, immunohistochemistry staining for BRAFV600E, clonal inference plot and evolutionary trajectory of the ECD and AML. (A) CT chest showing
basilar predominant septal line thickening (yellow arrows). (B) CT abdomen showing bilateral perinephric soft tissue thickening (“hairy kidney”) indicating
retroperitoneal fibrosis. (C) Immunohistochemistry staining for BRAFV600E in the Lung tissue (ECD specimen at 40x magnification). (D) Immunohistochemistry
staining for BRAFV600E in bone marrow (AML specimen at 40x magnification). (E) Clonal inference plot of single-nucleotide variants discovered from exome




low tumor cellularity of the ECD sample (~10%) necessi-
tated deeper sequencing (1349x coverage). Fourteen
somatic variants were identified, including known can-
cer-driving mutations in BRAFV600E and IDH2R140Q (Figure
1E and 1F, Table 1, and Online Supplementary Table 1). 
Clonal inference revealed that the BRAFV600E mutation
and 4 other mutations were present in a shared founding
clone, indicating a common cell of origin (Figure 1E and
1F). Five variants were AML-specific, while only one was
specific to the ECD (Table 1 and Online Supplementary
Table 1). The IDH2 mutation was present in a distinct
population of cells from the tumors, as confirmed by
sequencing of a non-malignant biopsy that contained
IDH2 but not the founding BRAFV600E mutation, marking
a concurrent hematopoietic clone that was not part of
either the ECD or AML.
There were five mutations conclusively shared
between the ECD (lung) and AML (bone marrow) speci-
mens (BRAF, DNAH6, NDUFB4, SI, and
ENSG00000252849) (Table 1 and Online Supplementary
Table 1). The presence of all 5 mutations in both the AML
and ECD samples provides exceptionally strong evidence
that these two malignancies were derived from the same
cell of origin. 
Though the cells of origin for ECD are still considered
unknown, previous studies have suggested that
hematopoietic/myeloid progenitor cells might be the pre-
cursors of histiocytic neoplastic cells in both ECD and
LCH.7-11 Additionally, a recent study observed that 10% of
adult patients with non-Langerhans histiocytosis had a
concomitant myeloid neoplasm.12 One study reported an
ECD/LCH mixed histiocytic neoplasm with an NRAS
mutation in ECD/LCH tissue as well as in bone marrow
after diagnosis of chronic myelomonocytic leukemia
(CMML).12 Another study reported on a patient with
mixed histiocytosis and BRAFV600E, TET2, and SRSF2
mutations in LCH cells from skin, and concurrent AML
with TET2 and SRSF2 mutations, suggesting a clonal
relationship between the two malignancies.11
Our patient had fluctuating monocytosis concurrent
with his ECD. We were unable to further analyze his
monocytosis with a bone marrow examination prior to
presentation with AML, and there was insufficient
banked peripheral blood material to investigate BRAF and
other mutations in monocytes circulating in blood. It is
therefore possible that the patient had CMML concurrent
with ECD that progressed to AML 26 months later. In
addition, our patient declined treatment with vemu-
rafenib for his ECD. The effect of targeted therapies like
Vemurafenib in preventing evolution of ECD to myeloid
malignancies has not been studied.
Though our data provides a catalog of single nucleotide
variants (SNVs) and small indel mutations, it is difficult to
identify with confidence the mutations that cooperated
with BRAF to drive malignant transformation. USP9X
that is a known tumor suppressor gene in pancreatic ade-
nocarcinoma,14 and SPI1 (PU.1) that acts as a tumor sup-
pressor gene in a fraction of patients with AML15 may
provide the “second hit” needed for leukemic transforma-
tion. The remainder of the mutations in the ECD were
not protein-altering, though additional cooperating
events may have existed in classes we were not powered
to detect (translocations, copy number alterations, etc.),
or transcriptional changes that were not assessed. 
This case confirms a common cell of origin for
BRAFV600E mutated ECD and BRAFV600E mutated AML in
one patient, as evidenced by shared BRAFV600E driver
mutation and several shared presumed passenger muta-
tions. This adds to the current body of evidence support-
ing the proposal for categorizing ECD as a
myeloid/myeloproliferative malignancy that can progress
to AML, and potentially, to other myeloid malignancies.
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